BRPI0410792B8 - compostos de anfetamina resistentes à dependencia - Google Patents

compostos de anfetamina resistentes à dependencia

Info

Publication number
BRPI0410792B8
BRPI0410792B8 BRPI0410792A BRPI0410792A BRPI0410792B8 BR PI0410792 B8 BRPI0410792 B8 BR PI0410792B8 BR PI0410792 A BRPI0410792 A BR PI0410792A BR PI0410792 A BRPI0410792 A BR PI0410792A BR PI0410792 B8 BRPI0410792 B8 BR PI0410792B8
Authority
BR
Brazil
Prior art keywords
compounds
abuse
amphetamine
compositions
bioavailability
Prior art date
Application number
BRPI0410792A
Other languages
English (en)
Portuguese (pt)
Inventor
Bishop Barney
Lauderback Christopher
Scott Moncrief James
Oberlender Rob
Krishnan Suma
Mickle Travis
Original Assignee
New River Pharmaceuticals Inc
Shire Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33555349&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0410792(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by New River Pharmaceuticals Inc, Shire Llc filed Critical New River Pharmaceuticals Inc
Publication of BRPI0410792A publication Critical patent/BRPI0410792A/pt
Publication of BRPI0410792B1 publication Critical patent/BRPI0410792B1/pt
Publication of BRPI0410792B8 publication Critical patent/BRPI0410792B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/901—Drugs of abuse, e.g. narcotics, amphetamine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/17—Nitrogen containing
    • Y10T436/173845—Amine and quaternary ammonium

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
BRPI0410792A 2003-05-29 2004-06-01 compostos de anfetamina resistentes à dependencia BRPI0410792B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47392903P 2003-05-29 2003-05-29
US56780104P 2004-05-05 2004-05-05
PCT/US2004/017204 WO2005000334A1 (en) 2003-05-29 2004-06-01 Abuse resistant amphetamine compounds

Publications (3)

Publication Number Publication Date
BRPI0410792A BRPI0410792A (pt) 2006-08-01
BRPI0410792B1 BRPI0410792B1 (pt) 2017-02-21
BRPI0410792B8 true BRPI0410792B8 (pt) 2021-05-25

Family

ID=33555349

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410792A BRPI0410792B8 (pt) 2003-05-29 2004-06-01 compostos de anfetamina resistentes à dependencia

Country Status (24)

Country Link
US (11) US7223735B2 (enExample)
EP (1) EP1644019B2 (enExample)
JP (2) JP4898445B2 (enExample)
KR (2) KR101159477B1 (enExample)
CN (1) CN1816346B (enExample)
AT (1) ATE545427T2 (enExample)
AU (1) AU2004251647B2 (enExample)
BE (1) BE2020C543I2 (enExample)
BR (1) BRPI0410792B8 (enExample)
CA (1) CA2527646C (enExample)
CY (1) CY1113130T1 (enExample)
DK (1) DK1644019T4 (enExample)
EA (1) EA010295B1 (enExample)
EG (1) EG26032A (enExample)
ES (1) ES2380622T5 (enExample)
IL (1) IL172212A (enExample)
MX (1) MXPA05012850A (enExample)
NL (1) NL301019I2 (enExample)
NO (1) NO20056211L (enExample)
NZ (1) NZ544162A (enExample)
PL (1) PL1644019T5 (enExample)
PT (1) PT1644019E (enExample)
SI (1) SI1644019T2 (enExample)
WO (1) WO2005000334A1 (enExample)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716452B1 (en) * 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US20070060500A1 (en) * 2000-08-22 2007-03-15 New River Pharmaceuticals Inc. Pharmaceutical compositions for prevention of overdose or abuse
US8394813B2 (en) * 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
US7338939B2 (en) * 2003-09-30 2008-03-04 New River Pharmaceuticals Inc. Abuse-resistant hydrocodone compounds
US7169752B2 (en) * 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US20060014697A1 (en) * 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
US7375082B2 (en) * 2002-02-22 2008-05-20 Shire Llc Abuse-resistant hydrocodone compounds
US20070066537A1 (en) * 2002-02-22 2007-03-22 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US7659253B2 (en) * 2002-02-22 2010-02-09 Shire Llc Abuse-resistant amphetamine prodrugs
US7700561B2 (en) * 2002-02-22 2010-04-20 Shire Llc Abuse-resistant amphetamine prodrugs
US7105486B2 (en) * 2002-02-22 2006-09-12 New River Pharmaceuticals Inc. Abuse-resistant amphetamine compounds
US8133881B2 (en) * 2003-01-13 2012-03-13 Shire Llc Carbohydrate conjugates to prevent abuse of controlled substances
NZ544162A (en) * 2003-05-29 2008-09-26 Shire Llc Abuse resistant amphetamine compounds
NZ546226A (en) * 2003-09-30 2009-03-31 Shire Llc Oxycodone conjugates for prevention of overdose or abuse
BRPI0720105A2 (pt) * 2006-12-11 2014-10-07 Kempharm Inc Conjugados de aminoácido não padrões de anfetamina e processos para fabricação e uso dos mesmos
WO2008098151A2 (en) * 2007-02-08 2008-08-14 Kempharm, Inc. Polar hydrophilic prodrugs of amphetamine and other stimulants and processes for making and using the same
PL2187873T3 (pl) * 2007-08-13 2019-01-31 Abuse Deterrent Pharmaceutical Llc Leki odporne na nadużywanie, metoda stosowania i metoda wytwarzania
US8318813B2 (en) * 2007-09-13 2012-11-27 Lcs Group, Llc Method of treating binge eating disorder
CN101555214B (zh) * 2008-04-08 2012-07-11 北京嘉事联博医药科技有限公司 苯基环丁基酰胺衍生物及其光学异构体、制备方法和用途
US8802681B2 (en) 2008-10-17 2014-08-12 Signature Therapeutics, Inc. Pharmaceutical compositions with attenuated release of phenolic opioids
US20100303903A1 (en) * 2009-05-26 2010-12-02 Shire Llc Methods of enhancing selective serotonin reuptake inhibitor effects in mammals
WO2010148305A1 (en) 2009-06-19 2010-12-23 Cambrex Charles City, Inc. Methods and compositions for preparation of amphetamine conjugates and salts thereof
JP2013503862A (ja) 2009-09-08 2013-02-04 シグネーチャー セラピューティクス，インク． 酵素切断可能なケトン修飾オピオイドプロドラッグとその任意選択のインヒビターとを含んでなる組成物
SMT201700578T1 (it) * 2009-11-20 2018-01-11 Tonix Pharma Holdings Ltd Metodo e composizioni per trattare i sintomi associati al disturbo da stress post-traumatico usando ciclobenzaprina
JP5094832B2 (ja) * 2009-12-25 2012-12-12 日東電工株式会社 粘着剤組成物および粘着シート
WO2011133347A1 (en) * 2010-04-21 2011-10-27 Pharmacofore, Inc. Compositions comprising trypsin-cleavable amphetamine prodrugs and inhibitors thereof
US20110262355A1 (en) 2010-04-21 2011-10-27 Jenkins Thomas E Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
ES2710617T3 (es) 2010-04-21 2019-04-26 Signature Therapeutics Inc Composiciones que comprenden profármacos de anfetamina escindibles enzimáticamente e inhibidores de los mismos
US9238020B2 (en) 2010-04-21 2016-01-19 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable phenol-modified tapentadol prodrug
JP2013526583A (ja) 2010-05-21 2013-06-24 リサーチ・トライアングル・インスティチュート フェニルモルホリンおよびその類似体
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
US20120010216A1 (en) * 2010-07-06 2012-01-12 Brown Arthur M Pharmaceutical compositions containing vanoxerine
WO2012056246A1 (en) 2010-10-28 2012-05-03 Shire Llc Combination treatment of major depressive disorder
US8779191B2 (en) * 2010-12-20 2014-07-15 Cambrex Charles City, Inc. Methods and compositions for preparing lisdexamfetamine and salts thereof
US8497237B2 (en) 2011-01-11 2013-07-30 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable oxycodone prodrug
ES2584634T3 (es) 2011-01-11 2016-09-28 Signature Therapeutics, Inc. Composiciones que comprenden un profármaco de oxicodona escindible enzimáticamente
US11998516B2 (en) 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
US8685916B2 (en) 2011-03-09 2014-04-01 Signature Therapeutics, Inc. Opioid prodrugs with heterocyclic linkers
EP2683394B1 (en) 2011-03-09 2021-01-06 Signature Therapeutics, Inc. Active agent prodrugs with heterocyclic linkers
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
US9028868B2 (en) 2011-03-23 2015-05-12 Ironshore Pharmaceuticals & Development, Inc. Methods and compositions for treatment of attention deficit disorder
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
WO2013011526A1 (en) * 2011-07-20 2013-01-24 Ind-Swift Laboratories Limited Process for preparation of lisdexamphetamine and salts thereof
US11571390B2 (en) 2013-03-15 2023-02-07 Othemo Life Sciences, Inc. Abuse deterrent compositions and methods of use
SG10201707528WA (en) 2013-03-15 2017-10-30 Tonix Pharmaceuticals Inc Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride
US11123310B2 (en) 2017-02-24 2021-09-21 Pharmapotheca, Llc Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms
US12208068B2 (en) * 2013-12-31 2025-01-28 Pharmapotheca A Inc. Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
MY186047A (en) 2014-09-18 2021-06-17 Tonix Pharma Holdings Ltd Eutectic formulations of cyclobenzaprine hydrochloride
US10544434B2 (en) 2015-06-29 2020-01-28 Noramco, Inc. Process for the preparation of lisdexamfetamine and related derivatives
WO2018098499A1 (en) * 2016-11-28 2018-05-31 Praxis Precision Medicines, Inc. Compounds and their methods of use
CA3046486A1 (en) * 2016-12-11 2018-06-14 Kempharm, Inc. Compositions comprising methylphenidate-prodrugs, processes of making and using the same
EP3459538B1 (en) 2017-09-20 2020-05-06 Sandoz AG Crystalline salts of a dextroamphetamine prodrug
AU2018351936A1 (en) * 2017-10-06 2020-05-14 Fundação Calouste Gulbenkian Treatment of obesity-related conditions
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
SG11202004799TA (en) 2017-12-11 2020-06-29 Tonix Pharma Holdings Ltd Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
US11136295B2 (en) 2018-10-29 2021-10-05 Kempharm, Inc. D-amphetamine compounds, compositions, and processes for making and using the same
DE112020001032T5 (de) 2019-03-02 2021-12-09 Chemapotheca, Llc Verfahren zur Herstellung von Levoamphetamin
US20220175699A1 (en) * 2019-03-06 2022-06-09 Ensysce Biosciences, Inc. Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof
KR20220009954A (ko) 2019-04-17 2022-01-25 컴퍼스 패쓰파인더 리미티드 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법
JP2023549405A (ja) * 2020-11-18 2023-11-24 マインド メディシン， インコーポレイテッド 心理療法を補助するためのｍｄｍａプロドラッグ
WO2022235530A1 (en) * 2021-05-05 2022-11-10 Mind Medicine, Inc. Mdma enantiomers
AU2022283967A1 (en) 2021-06-03 2024-01-18 Arcadia Medicine, Inc. Enantiomeric entactogen compositions and methods of their use
CA3230025A1 (en) 2021-09-29 2023-04-06 Lynn Kirkpatrick Enzyme-cleavable methadone prodrugs and methods of use thereof
CN119013009A (zh) * 2022-01-07 2024-11-22 巴塞尔大学医院 用于辅助心理治疗的r-mdma和s-mdma
JP2025527481A (ja) * 2022-08-17 2025-08-22 トランセンド セラピューティクス，インコーポレイテッド フェネチルアミンおよびカチノン前駆体

Family Cites Families (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US200300A (en) * 1878-02-12 Improvement in instruments for smoothing and leveling the teeth of horses
US3028430A (en) * 1955-03-28 1962-04-03 Parke Davis & Co Process for the production of optically active isomers of amphetamine
US3028395A (en) * 1955-03-28 1962-04-03 Parke Davis & Co Process for the resolution of optically active acids
DE1493824A1 (de) 1964-01-27 1969-05-22 Hoffmann La Roche Verfahren zur Herstellung von Aminocarbonsaeureamiden
CH406567A (de) 1964-02-10 1966-01-31 Inventio Ag Einrichtung zur Steuerung der Sollwertgrösse während des Verzögerungsvorganges bei Aufzügen mit drehzahlgeregeltem Antrieb
GB1091089A (en) 1965-08-20 1967-11-15 Pierre Wirth Organic base salts of n-carbamyl-aspartic acids
GB1112347A (en) 1965-08-20 1968-05-01 Pierre Wirth Salts of organic bases with n-carbamyl-l-glutamic acid
US3846399A (en) * 1969-04-10 1974-11-05 Merck & Co Inc Process for controlled stepwise synthesis of polypeptides
US3676492A (en) * 1970-12-09 1972-07-11 Aldrich Chem Co Inc Amino acid amides of disubstituted phenethylamines
US3843796A (en) † 1971-04-26 1974-10-22 Merck & Co Inc Antihypertensive agents
US3706831A (en) * 1971-05-14 1972-12-19 Abbott Lab Method for treatment of drug addiction
US3975342A (en) * 1972-05-15 1976-08-17 Biological Developments, Inc. Tyrosyl-class antigenic conjugates, their preparation and antibodies raised thereto
US3884898A (en) * 1972-08-18 1975-05-20 Syva Co Normorphine derivatives bonded to proteins
US3843696A (en) * 1972-09-05 1974-10-22 Syva Co Methadone analog compounds
US3878187A (en) * 1972-09-11 1975-04-15 Syva Co Polypeptide derivatives of amphetamine and analogs for immunoassays
US3878487A (en) * 1973-08-02 1975-04-15 Alexandr Lvovich Irzhavsky Electromechanical disc filter
US3998799A (en) * 1973-11-02 1976-12-21 Interx Research Corporation Novel, transient pro-drug forms of l-dopa
US3945342A (en) * 1973-11-08 1976-03-23 Xerox Corporation Magnetic brush support member
US4040907A (en) * 1974-06-20 1977-08-09 Syva Company Iodothyronine enzyme conjugates
GB1507144A (en) * 1974-07-10 1978-04-12 Post Office Apparatus for drawing dielectric optical waveguides
US4000280A (en) * 1974-08-14 1976-12-28 Astra Lakemedel Aktiebolag Pharmaceutical compositions containing an amphetamine derivative for the alleviation of anxiety or treatment of depression
DE2449333A1 (de) * 1974-10-17 1976-04-29 Bosch Gmbh Robert Kraftstoffeinspritzpumpe fuer brennkraftmaschinen
US4025501A (en) * 1975-03-20 1977-05-24 Syva Company Polypeptide propoxyphene derivatives for immunoassay reagents
US4064235A (en) * 1975-08-21 1977-12-20 Eisai Co., Ltd. Dopamine derivative compounds, preparation thereof and medicine containing same
US4043989A (en) * 1975-09-11 1977-08-23 Syva Company Oxazepam derivatives for immunoassay reagents
US4064236A (en) * 1975-12-23 1977-12-20 Merck & Co., Inc. Peptide carbazates and pharmaceutical composition
GB1592552A (en) * 1976-12-10 1981-07-08 Inst Nat Sante Rech Med Pseudopeptides used as medicaments
JPS54155675A (en) * 1978-05-30 1979-12-07 Matsushita Electronics Corp Small-sized fluorescent lamp
JPS557242A (en) 1978-06-30 1980-01-19 Tanabe Seiyaku Co Ltd Phenethylamine derivative
JPS5528915A (en) 1978-08-18 1980-02-29 Tanabe Seiyaku Co Ltd Benzyl alcohol derivative and its preparation
US4356166A (en) * 1978-12-08 1982-10-26 University Of Utah Time-release chemical delivery system
DE3008265A1 (de) * 1980-03-04 1981-09-17 Siemens AG, 1000 Berlin und 8000 München Verfahren zum sichtbarmachen von stationaeren waermeuebergangskoeffizientenfeldern auf photochemischem wege
US4399121A (en) * 1981-11-04 1983-08-16 Miles Laboratories, Inc. Iodothyronine immunogens and antibodies
US4427660A (en) * 1982-03-03 1984-01-24 Research Corporation Formyl-methionyl chemotatic peptide antibiotic conjugates useful in treating infections
HU185535B (en) * 1982-05-25 1985-02-28 Mta Koezponti Hivatala Process for preparing new gonadoliberin derivatives
US4457907A (en) * 1982-08-05 1984-07-03 Clear Lake Development Group Composition and method for protecting a therapeutic drug
US4650675A (en) * 1983-08-18 1987-03-17 The Children's Medical Center Corporation Oligonucleotide conjugates
JPS60166657A (ja) * 1984-02-10 1985-08-29 Nitto Boseki Co Ltd アルギニル−３−カルボキシ−４−ヒドロキシアニリド
DE3581471D1 (de) * 1984-10-19 1991-02-28 Battelle Memorial Institute Durch mikroorganismen abbaubares polypeptid und seine verwendung fuer die fortschreitende abgabe von medikamenten.
GB8500209D0 (en) 1985-01-04 1985-02-13 Ceskoslovenska Akademie Ved Synthetic polymeric drugs
US4863735A (en) * 1985-02-19 1989-09-05 Massachusetts Institute Of Technology Biodegradable polymeric drug delivery system with adjuvant activity
US4801575A (en) * 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4902505A (en) * 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
IN165717B (enExample) * 1986-08-07 1989-12-23 Battelle Memorial Institute
DK406686D0 (da) * 1986-08-26 1986-08-26 Hans Bundgaard Carboxylsyrederivater
US5994392A (en) * 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US5169933A (en) * 1988-08-15 1992-12-08 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5026827A (en) * 1988-09-02 1991-06-25 Matsushita Electric Industrial Co., Ltd. Amphetamine-protein complex as immunogen for obtaining antibodies specific to methamphetamine
US5233025A (en) * 1988-09-02 1993-08-03 Matsushita Electric Industrial Co., Ltd. Amphetamine protein complex as immunogen for obtaining antibodies specific to methamphetamine
US4960790A (en) * 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
FR2649247B1 (fr) * 1989-06-30 1991-09-13 Thomson Csf Detecteur infrarouge a base de materiau pyroelectrique
US5767227A (en) 1989-11-03 1998-06-16 Lotus Biochemical Corp. Iodothyronine polymers
US5219564A (en) * 1990-07-06 1993-06-15 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
JPH078853B2 (ja) 1990-08-30 1995-02-01 田辺製薬株式会社 ドーパミン誘導体の製法
IT1244873B (it) * 1990-09-12 1994-09-12 Depha Team Srl Derivati dell'acido 5-aminosalicilico (5-asa) per la terapia delle infiammazioni croniche intestinali
EP0477931B1 (en) 1990-09-28 1994-08-17 Mercian Corporation Novel adriamycin derivatives
US5238714A (en) 1990-10-02 1993-08-24 Board Of Regents, The University Of Texas System Efficient microcapsule preparation and method of use
US5863899A (en) * 1991-04-01 1999-01-26 Cortech, Inc. Bradykinin antagonists
JP2613502B2 (ja) * 1991-05-31 1997-05-28 東洋紡績株式会社 制振材料用粘弾性樹脂組成物
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5470997A (en) * 1992-04-06 1995-11-28 Biosite Diagnostics Incorporated Amphetamine derivatives and protein and polypeptide amphetamine derivative conjugates and labels
US5811127A (en) * 1992-06-15 1998-09-22 Emisphere Technologies, Inc. Desferrioxamine oral delivery system
CA2096495C (en) * 1992-06-16 2002-07-09 Kathy Palmer Ordonez Dual analyte immunoassay
GB9213077D0 (en) 1992-06-19 1992-08-05 Erba Carlo Spa Polymerbound taxol derivatives
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
GB9215780D0 (en) 1992-07-24 1992-09-09 Univ London Pharmacy Peptide compounds
US6093391A (en) 1992-10-08 2000-07-25 Supratek Pharma, Inc. Peptide copolymer compositions
US5298410A (en) * 1993-02-25 1994-03-29 Sterling Winthrop Inc. Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life
US5891459A (en) 1993-06-11 1999-04-06 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
DE69426629T2 (de) * 1993-08-02 2001-08-02 Commonwealth Scientific And Industrial Research Organisation, Campbell Therapeutische verbindung - fettsäurekonjugate
WO1995012604A1 (en) 1993-11-05 1995-05-11 Aktiebolaget Astra Novel amino acid derivatives
WO1995014033A1 (en) 1993-11-19 1995-05-26 Aktiebolaget Astra Novel dipeptide derivatives
GB9401891D0 (en) 1994-02-01 1994-03-30 Boots Co Plc Therapeutic agents
US6051685A (en) * 1994-03-11 2000-04-18 Daiichi Pharmaceuticals Co., Ltd. Peptide derivatives
RU2152787C2 (ru) * 1994-06-02 2000-07-20 Дан Рига Лекарство против стресса, против снижения уровня активности и против старения и способ его получения
JP2526811B2 (ja) 1994-07-22 1996-08-21 田辺製薬株式会社 フェネチルアミン誘導体及びその製法
US5716614A (en) 1994-08-05 1998-02-10 Molecular/Structural Biotechnologies, Inc. Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier
US5910569A (en) 1994-11-22 1999-06-08 Lotus Biochemical Corporation Iodothyronine polymers
DE19504387A1 (de) * 1995-02-11 1996-08-22 Dufa Deutsche Uhrenfabr Gmbh Schrittmotor
US5846743A (en) 1995-02-22 1998-12-08 Brigham And Women's Hospital, Inc. Polyphoshoinositide binding peptides for intracellular drug delivery
US5670477A (en) 1995-04-20 1997-09-23 Joseph F. Poduslo Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents
EP0831817B1 (en) 1995-06-07 2001-03-14 Joel K. Swadesh Antigen-processing cell-targeted conjugates comprising a polyamino acid backbone and a non-steroidal anti-inflammatory agent
DE19526274A1 (de) * 1995-07-19 1997-01-23 Bayer Ag Verbesserung der Verträglichkeit von pharmazeutisch wirksamen beta-Aminosäuren
US5762909A (en) 1995-08-31 1998-06-09 General Electric Company Tumor targeting with polymeric molecules having extended conformation
US5851536A (en) 1995-11-22 1998-12-22 University Of Washington Therapeutic delivery using compounds self-assembled into high axial ratio microstructures
US6361957B1 (en) * 1999-08-03 2002-03-26 Glytech, Inc. Assay for D-serine transport antagonist and use for treating psychosis
WO1997024436A2 (en) * 1995-12-28 1997-07-10 Takeda Chemical Industries, Ltd. Ligand polypeptides for the g-protein-coupled receptor protein, their production and use
WO1997033552A1 (en) 1996-03-12 1997-09-18 Pg-Txl Company, L.P. Water soluble paclitaxel prodrugs
GB9606975D0 (en) 1996-04-02 1996-06-05 Univ Birmingham Anti-tumor agent
US6030941A (en) 1996-05-01 2000-02-29 Avi Biopharma, Inc. Polymer composition for delivering substances in living organisms
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5952294A (en) 1996-07-31 1999-09-14 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peptidyl prodrugs and methods of making and using the same
US6013633A (en) 1997-08-07 2000-01-11 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
DE19640970A1 (de) * 1996-10-04 1998-04-16 Bayer Ag Modifizierte Cytostatika
US5948750A (en) 1996-10-30 1999-09-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
AU7282498A (en) 1997-05-01 1998-11-24 Emory University Bioactive peptides derived from cocaine and amphetamine regulated transcript protein
AU734827B2 (en) 1997-05-21 2001-06-21 Board Of Trustees Of The Leland Stanford Junior University Composition and method for enhancing transport across biological membranes
TW460478B (en) 1997-08-15 2001-10-21 Chugai Pharmaceutical Co Ltd Phenethylamine derivatives
AU1825299A (en) 1997-12-17 1999-07-05 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
WO1999038869A1 (en) 1998-01-29 1999-08-05 Monash University Therapeutic compounds
US6632922B1 (en) * 1998-03-19 2003-10-14 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
US6686446B2 (en) * 1998-03-19 2004-02-03 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
US6680365B1 (en) * 1998-03-19 2004-01-20 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
US6473669B2 (en) * 1998-07-03 2002-10-29 Kimberly-Clark Worldwide, Inc. Controlling web tension, and accumulating lengths of web, by actively controlling velocity and acceleration of a festoon
US6696558B2 (en) * 1998-09-09 2004-02-24 The Burnham Institute Bag proteins and nucleic acid molecules encoding them
JP2000173537A (ja) * 1998-09-29 2000-06-23 Toshiba Lighting & Technology Corp 低圧水銀蒸気放電灯および照明装置
US7083808B2 (en) * 1998-12-17 2006-08-01 Euro-Celtique S.A. Controlled/modified release oral methylphenidate formulations
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US7060708B2 (en) * 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US6716452B1 (en) * 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
CA2277855A1 (fr) 1999-07-14 2001-01-14 Solvision Methode et systeme de mesure de la hauteur des billes de soudure d'un circuit imprime
US6384020B1 (en) * 1999-07-14 2002-05-07 Shire Laboratories, Inc. Rapid immediate release oral dosage form
US6806330B1 (en) * 1999-12-17 2004-10-19 Dow Global Technologies Inc. Amine organoborane complex polymerization initiators and polymerizable compositions
US20020099013A1 (en) 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
US20070060500A1 (en) * 2000-08-22 2007-03-15 New River Pharmaceuticals Inc. Pharmaceutical compositions for prevention of overdose or abuse
WO2003034980A2 (en) † 2000-11-14 2003-05-01 New River Pharmaceuticals Inc. A novel pharmaceutical compound containing abacavir sulfate and methods of making and using same
US20020098999A1 (en) 2000-10-06 2002-07-25 Gallop Mark A. Compounds for sustained release of orally delivered drugs
US6992076B2 (en) 2000-10-06 2006-01-31 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
AU2001296703A1 (en) 2000-10-06 2002-04-15 Xenoport, Inc. Bile acid prodrugs of l-dopa and their use in the sustained treatment of parkinsonism
WO2002039998A2 (en) * 2000-11-01 2002-05-23 Sention, Inc. Methods and compositions for regulating memory consolidation
US6472228B2 (en) * 2000-12-04 2002-10-29 Lifepoint, Inc. Composition and methods for synthesis of novel tracers for detecting amphetamine and methamphetamine in samples
MX241166B (es) 2001-06-29 2006-10-16 Ovonic Battery Co Bacteria de almacenamiento de hidrogeno; electrodo de niquel positivo; material activo de electrodo positivo y metodos para fabricarlos.
US6740641B2 (en) 2001-07-27 2004-05-25 Euro-Celtique, S.A. Sugar derivatives of hydromorphone, dihydromorphine and dihydromorphine, compositions thereof and uses for treating or preventing pain
US7338939B2 (en) * 2003-09-30 2008-03-04 New River Pharmaceuticals Inc. Abuse-resistant hydrocodone compounds
US7169752B2 (en) * 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US20070066537A1 (en) * 2002-02-22 2007-03-22 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US7375082B2 (en) 2002-02-22 2008-05-20 Shire Llc Abuse-resistant hydrocodone compounds
US20060014697A1 (en) * 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
WO2003024480A2 (en) * 2001-09-14 2003-03-27 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
US6399828B1 (en) * 2001-10-29 2002-06-04 Boehringer Ingelheim Chemicals, Inc. Preparation of amphetamines from phenylpropanolamines
CA2472917A1 (en) * 2002-01-08 2003-07-17 New River Pharmaceuticals Inc. Dendritic encapsulation of active agents
US7700561B2 (en) * 2002-02-22 2010-04-20 Shire Llc Abuse-resistant amphetamine prodrugs
US7659253B2 (en) † 2002-02-22 2010-02-09 Shire Llc Abuse-resistant amphetamine prodrugs
KR100822498B1 (ko) * 2002-02-22 2008-04-16 샤이어 엘엘씨 규제된 물질의 남용을 방지하기 위한 새로운 서방성 약학화합물
US7105486B2 (en) * 2002-02-22 2006-09-12 New River Pharmaceuticals Inc. Abuse-resistant amphetamine compounds
AU2003213259C1 (en) * 2002-02-22 2009-07-16 Shire Llc Use of peptide-drug conjugation to reduce inter-subject variability of drug serum levels
US6913768B2 (en) * 2002-09-24 2005-07-05 Shire Laboratories, Inc. Sustained release delivery of amphetamine salts
US8133881B2 (en) * 2003-01-13 2012-03-13 Shire Llc Carbohydrate conjugates to prevent abuse of controlled substances
AR042938A1 (es) * 2003-02-06 2005-07-06 Wyeth Corp Uso del cci-779 en el tratamiento de la fibrosis hepatica
MXPA05009757A (es) 2003-03-13 2005-12-05 Controlled Chemicals Inc Conjugados de oxicodona con menor potencial de abuso y duracion de accion extendida.
NZ544162A (en) 2003-05-29 2008-09-26 Shire Llc Abuse resistant amphetamine compounds
NZ546226A (en) * 2003-09-30 2009-03-31 Shire Llc Oxycodone conjugates for prevention of overdose or abuse

Also Published As

Publication number Publication date
US7678770B2 (en) 2010-03-16
HK1088254A1 (en) 2006-11-03
EA010295B1 (ru) 2008-08-29
DK1644019T3 (da) 2012-05-14
WO2005000334A1 (en) 2005-01-06
IL172212A (en) 2015-06-30
IL172212A0 (en) 2007-12-03
ATE545427T2 (de) 2012-03-15
NO20056211L (no) 2006-02-27
US20090181898A1 (en) 2009-07-16
US7662787B2 (en) 2010-02-16
US20080086016A1 (en) 2008-04-10
US20100105781A1 (en) 2010-04-29
PT1644019E (pt) 2012-05-23
EA200501895A1 (ru) 2006-06-30
ES2380622T5 (es) 2018-05-30
KR101170840B1 (ko) 2012-08-03
US20090124696A1 (en) 2009-05-14
MXPA05012850A (es) 2006-05-17
EG26032A (en) 2012-12-12
DK1644019T4 (en) 2018-04-23
US20090186828A1 (en) 2009-07-23
SI1644019T2 (en) 2018-04-30
CA2527646A1 (en) 2005-01-06
CN1816346B (zh) 2013-04-17
KR101159477B1 (ko) 2012-07-02
JP4898445B2 (ja) 2012-03-14
BRPI0410792B1 (pt) 2017-02-21
CA2527646C (en) 2011-08-23
EP1644019A1 (en) 2006-04-12
US7718619B2 (en) 2010-05-18
CN1816346A (zh) 2006-08-09
US20090186945A1 (en) 2009-07-23
US20090186825A1 (en) 2009-07-23
US20100004336A1 (en) 2010-01-07
KR20110061654A (ko) 2011-06-09
CY1113130T1 (el) 2016-04-13
PL1644019T3 (pl) 2012-07-31
US20050038121A1 (en) 2005-02-17
PL1644019T5 (pl) 2018-06-29
US20090209471A1 (en) 2009-08-20
NZ544162A (en) 2008-09-26
JP2007500242A (ja) 2007-01-11
NL301019I2 (nl) 2020-07-29
AU2004251647B2 (en) 2010-01-14
EP1644019A4 (en) 2010-09-01
US7223735B2 (en) 2007-05-29
JP2012006978A (ja) 2012-01-12
ES2380622T3 (es) 2012-05-16
BE2020C543I2 (enExample) 2023-08-09
US20090192093A1 (en) 2009-07-30
KR20060073538A (ko) 2006-06-28
EP1644019B1 (en) 2012-02-15
BRPI0410792A (pt) 2006-08-01
EP1644019B2 (en) 2018-02-21
AU2004251647A1 (en) 2005-01-06
SI1644019T1 (sl) 2012-06-29

Similar Documents

Publication Publication Date Title
BRPI0410792B8 (pt) compostos de anfetamina resistentes à dependencia
Olliaro Mode of action and mechanisms of resistance for antimalarial drugs
BR0209558A (pt) Novos compostos de arilsulfonamida para o tratamento de obesidade, diabetes tipo ii e distúrbios do snc
BR0212008A (pt) Uso de um composto ou de um sal, solvato ou pró-medicamento deste, composição farmacêutica, composto ou um sal, solvato ou pró-medicamento deste, e, processo para a preparação deste
NO20055837L (no) Immunsupprimerende forbindelser og sammensetninger
BR0214023A (pt) Derivados de 1,2,4-tiadiazólio como moduladores de receptor de melanocortina
BRPI0409258A (pt) processo para resolução de aminas que são úteis para o tratamento de distúrbios associados com a sìndrome de resistência à insulina
BR0003313A (pt) Novos compostos diméricos substituìdos, um processo para a preparação dos mesmos e composições farmacêuticas que contêm os mesmos
BRPI0406221A (pt) Bases altamente puras de monoésteres de 3,3-difenilpropilamina
WO2006121552A3 (en) Abuse-resistant amphetamine prodrugs
BR0308837A (pt) Composto, composição, método e medicamento para o tratamento de infecções bacterianas, psorìase ou artrite em mamìferos, método e medicamento para o tratamento de toxicidade devido a quimioterapia em um paciente, composição farmacêutica, processo para a preparação de um composto e processo para a conversão dos compostos da fórmula (i) em compostos adicionais da fórmula (i)
BR0002606A (pt) Processo para preparar sertralina a partir de tetralona quiral
BR0108840A (pt) Composto, prodroga, processo para produzir um composto, composição farmacêutica, método para prevenir ou tratar doenças inflamatórias, e, uso de um composto
BR0314811A (pt) Composto, uso do mesmo, e, intermediário de sìntese
BRPI0414148A (pt) derivados de imidazol
BR0013306A (pt) Processos úteis na sìntese de compostos antipicornavirais
BRPI0411068B8 (pt) análogos de colchicosídeos
BRPI0504780A (pt) compostos de benzotiadiazina, processo para sua preparação e composições farmacêuticas contendo os mesmos
DK1645558T3 (da) Piperazinylpyraziner som serotonin 5-HT2C receptormodulatorer
BR0202674A (pt) Compostos de benzenossulfonamida, processo para a sua preparação e composições farmacêuticas contendo os mesmos
BR9902525A (pt) Processo para compostos de ácido pirrolidinil-hidroxâmico
BR0100604A (pt) Compostos de ácido 6-sulfamoil-3-quinolilfosfÈnico, processo para suas preparações e composições farmacêuticas contendo os mesmos
BRPI0417338A (pt) formas de dosagem de azitromicina multiparticulada por processos a base de lìquido
Šunjić et al. Efavirenz
Hart et al. Hypotension Harry: Fatal Forty DDI: nicardipine, clarithromycin, CYP3A4

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: SHIRE LLC (US)

Free format text: TRANSFERIDO DE: NEW RIVER PHARMACEUTICALS INC.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: A61K 38/00

Ipc: A61K 38/00 (2006.01), A61P 3/04 (2006.01)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B17A Notification of administrative nullity (patentee has 60 days time to reply to this notification)
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/06/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25A Requested transfer of rights approved
B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 25.1 NA RPI NO 2640 DE 10/08/2021 POR TER SIDO INDEVIDA.

B25A Requested transfer of rights approved
B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: "INPI NO 52402.001560/2024-38 ORIGEM: 7A VARA FEDERAL CIVEL DA SJDF (TRF1) PROCESSO NO: 1073531-19.2023.4.01.3400 ACAO PELO PROCEDIMENTO COMUM AUTOR: TAKEDA PHARMACEUTICAL COMPANY LIMITED REU(S): INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL ? INPI, AGENCIA NACIONAL DEVIGILANCIA SANTIARIA ? ANVISA E UNIAO"

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI NO 52402.001132/2025-96 ORIGEM: GAB. 36 - DESEMBARGADORA FEDERAL ROSANA NOYA ALVES WEIBEL KAUFMANN (TRF1 PROCESSO NO: 1032954-77.2024.4.01.0000 SUB JUDICE COM PEDIDO DE ANTECIPACAO DE TUTELA AUTOR: TAKEDA PHARMACEUTICAL COMPANY LIMITED REU(S): AGENCIA NACIONAL DE VIGILANCIA SANTIARIA ? ANVISA, UNIAO E INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI